Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rifampin to Reduce Elevated Levels of Blood and Urine Calcium in Patients With Inactivating Mutations in the CYP24A1 Gene

NCT03301038 is registered in ClinicalTrials.gov with Children's Hospital of Philadelphia as lead sponsor.

NCT NCT03301038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03301038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rifampin to Reduce Elevated Levels of Blood and Urine Calcium in Patients With Inactivating Mutations in the CYP24A1 Gene
Lead sponsor
Children's Hospital of Philadelphia
Phase
Phase 2
Overall status
Recruiting
Start date
July 25, 2018
Completion date
December 1, 2030
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

genetic disease, hypercalcemia, idiopathic, of infancy, hypercalciuria, hypercalciuric hypercalcemia, idiopathic infantile hypercalcaemia - severe form, idiopathic infantile hypercalcemia - mild form